RNAC

Cartesian Therapeutics Inc.

RNAC.US cartesiantherapeutics.com + Research + Basket
CIK 0001453687
Employees 75
Phone 301 348 8698
Fiscal year end December
IPO Jun 22, 2016
Address 7495 New Horizon Way, Frederick, MD, United States, 21703
6.75
+0.06 (+0.90%)
USD · NASDAQ
52-week range
5.60
11.00
Trading at 21% of the 52-week range
Market Cap
195.45M
P/E Ratio
0.00
Forward P/E
25.06
Book Value
-4.17
Div. Yield
N/A
% Institutions
29.45%
% Insiders
52.13%

1 Year

-17.7%

3 Year

-82.1%

10 Year

-98.7%
Description

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Actions

Add an action for RNAC.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Carsten Brunn Ph.D. President, CEO & Chairman of the Board 1971
Mr. Blaine T. Davis Chief Financial Officer 1974
Dr. Emily English Ph.D. Chief Operating Officer 1980
Ms. June Seymour Chief Accounting Officer 1978
Mr. Matthew Bartholomae J.D. General Counsel & Secretary NA
Dr. Peter G. Traber M.D. Head of R&D 1955

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jan 06, 2026 Blaine Davis N/A Sale 10.59K $6.82 $72.23K SEC
Jan 06, 2026 Milos Miljkovic N/A Sale 3.57K $6.82 $24.37K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Squarepoint Ops LLC 2.25M Jun 30, 2026 7.45% $0.03 0.72%
BlackRock Inc 819.24K Jun 30, 2026 2.71% $0.00 36.74%
Vanguard Capital Management, LLC 555.82K Jun 30, 2026 1.84% $0.00 36.37%
FMR Inc 368.43K Jun 30, 2026 1.22% $0.00 -53.93%
Geode Capital Management, LLC 356.53K Jun 30, 2026 1.18% $0.00 35.20%
AQR Capital Management LLC 356.46K Jun 30, 2026 1.18% $0.00 324.25%
683 Capital Management LLC 330.00K Mar 31, 2026 1.09% $0.11 17.86%
Millennium Management LLC 309.89K Jun 30, 2026 1.02% $0.00 8.99%
Two Sigma Investments LLC 296.29K Jun 30, 2026 0.98% $0.00 77.09%
State Street Corp 249.21K Jun 30, 2026 0.82% $0.00 24.40%
Marshall Wace Asset Management Ltd 232.92K Jun 30, 2026 0.77% $0.00 -7.25%
UBS Group AG 208.65K Jun 30, 2026 0.69% $0.00 52.48%
Jupiter Topco LLC 200.91K Jun 30, 2026 0.66% $0.00 0.00%
Privium Fund Management B.V. 151.68K Jun 30, 2026 0.50% $0.29 -15.32%
Northern Trust Corp 105.70K Jun 30, 2026 0.35% $0.00 14.90%
ADAR1 Capital Management LLC 98.88K Jun 30, 2026 0.33% $0.05 0.00%
Vanguard Fiduciary Trust Co 91.85K Jun 30, 2026 0.30% $0.00 30.67%
Vanguard Portfolio Management, LLC 87.32K Jun 30, 2026 0.29% $0.00 44.13%
Diadema Partners LP 87.06K Jun 30, 2026 0.29% $0.11 0.00%
Bank of America Corp 84.62K Jun 30, 2026 0.28% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 376.31K 1.24% ▲ 0.00% Sep 30, 2026
2 Fidelity Select Biotechnology 366.55K 1.21% ▲ 0.00% Aug 31, 2026
3 iShares Russell 2000 ETF 340.31K 1.12% ▼ 1.13% Sep 30, 2026
4 Janus Henderson Small Cap Gr Alpha ETF 195.35K 0.65% ▲ 4.46% Sep 30, 2026
5 Fidelity Small Cap Index 144.04K 0.48% ▲ 0.74% Jul 31, 2026
6 iShares Russell 2000 Value ETF 95.30K 0.32% ▲ 0.15% Sep 30, 2026
7 Vanguard Russell 2000 ETF 75.95K 0.25% ▲ 1.05% Sep 30, 2026
8 Fidelity Extended Market Index 69.49K 0.23% ▼ 0.53% Aug 31, 2026
9 iShares Micro-Cap ETF 42.09K 0.14% ▼ 0.68% Sep 30, 2026
10 Stt Strt SPDR® Russell2000 US SmCapETF 36.38K 0.12% ▼ 6.49% Sep 30, 2026

Financial Highlights

▼
Market Cap: $195.45M
EBITDA: $-96.05M
PEG Ratio: $0.00
Book Value: $-4.17
Earnings/Share: $-5.97
Profit Margin: 0.00%
Operating Margin: -6,679.69%
ROA (TTM): -17.43%
ROE (TTM): -7,029.26%
Revenue (TTM): $1.48M
Revenue/Share (TTM): $0.06
Earnings Growth (YOY): -8.00%
Revenue Growth (YOY): -92.90%

Valuation Metrics

Enterprise Value: $106.25M
Trailing P/E: 0.00
Forward P/E: 25.06

Shares Statistics

Shares Outstanding: 30.26M
Shares Float: 11.49M
% Insiders: 52.13%
% Institutions: 29.45%
Short % Float: 13.51%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$2.80M
Gross Profit
subtotal
$2.80M
SG&A
adjust
$-31.47M
R&D
adjust
$-58.03M
Operating Income
subtotal
$-86.71M
Other / Non-Operating Items
adjust
$-43.60M
Net Income
subtotal
$-130.30M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about RNAC.US!